Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

3rd Pharma Meets AI Conference 2027

3rd Pharma Meets AI Conference on 19 and 20 April 2027 in Barcelona, hosted by UBIQ Events. Director-level executives from leading pharmaceutical companies share their expertise and real-world case studies on how artificial intelligence is...

World Congress of Bronchology and Interventional Pulmonology 2026

We are excited to announce that the World Congress of Bronchology and Interventional Pulmonology 2026 will be hosted by the Thoracic Society of Australia and New Zealand in the vibrant city of Melbourne, Australia. We are excited to announce that...

3rd Global Summit on Heart and Cardiovascular Care 2026

3rd Global Summit on Heart and Cardiovascular Care” (Heart Congress 2026), taking place on November 26–27, 2026, in Barcelona, Spain as a HYBRID EVENT—offering participants the flexibility to join in person or virtually from anywhere across the...

VietPharma&Tech 2026

2026 / The International Exhibition on Analytical and Laboratory Equipment in Vietnam - VietLab Expo 2024 from November 21 - 23, 2026 at Saigon Exhibition & Convention Center (SECC). Vietnam Medical Devices Association highly appreciates Vietnam...

SHARx’s Paul Pruitt Warns That Patent Expiration Does Not Guarantee Immediate Savings

A drug nearing patent expiration may seem like relief from high prices, but lower-cost competition can still take years to reach the market. Employers cannot control when a patent expires, a lawsuit is resolved, or when a biosimilar reaches the...

Seawolf Therapeutics Launches With $100 Million to Advance DNA-Based Therapies

Seawolf Therapeutics announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform. Founding investor Versant Ventures led the seed round, followed by the...

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data at ASH 2026, Demonstrating Promising Leukemia Treatment Results

poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana. The research, described in Abstract #2375, supports the potential of Eureka...

Bruker Announces the Appointment of Institute Director, Biopharma Entrepreneur, and Immunology Leader Dr. Eicke Latz to Its Board of Directors

that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized medical institute director, physician-scientist, successful biopharma...

CS Analytical to Offer Testing Services for Sunscreen Ingredients Used in Pharmaceutical and Cosmetic Products

CS Analytical (CSA), doing business as Raw Material Analytical (RMA), a cGMP laboratory dedicated to advancing product quality and patient safety, today announced that it is set to offer analytical testing for sunscreen ingredients used in...

6th International Conference on Cardiology 2026

Conference on Cardiology. Held in the vibrant city of Bangkok, Thailand, this prestigious event will take place on November 13–14, 2026. 6th International Conference on Cardiology. Held in the vibrant city of Bangkok, Thailand, this prestigious...

VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline

of VectorY’s lead program, VTx-002, through key clinical milestones, including the final readout of the PIONEER-ALS® Phase 1/2 clinical study. The global study is evaluating VTx-002 in people living with amyotrophic lateral sclerosis (ALS). In...

ProBio Signs Exclusive Global Licensing Agreement with AbTis for Next-Generation ADC Development

ProBio, a global contract research, development, and manufacturing organization announced that it has entered into an exclusive global licensing agreement with AbTis Co., Ltd., a South Korean biotechnology company and subsidiary of Dong-A ST,...

Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

Waters Corporation announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides pathologists and...

Bayer’s SUNHARBO® (asundexian) Receives FDA Approval for Stroke Risk Reduction

with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). Reducing the risk of a stroke after an initial event is often referred to as...

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

eligibility for filling a prescription of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%. To access the YUVEZZI telehealth program, visit orderYUVEZZI.com or call 800-204-3511 for more information. The YUVEZZI program...

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated statistically significant superiority in ACR50 joint outcomes versus risankizumab at Week 16 in...

Avanzanite Announces an Exclusive Agreement to License and Market Zemcelpro® in Europe

and nephrology with stem cell therapy and hematology oncology. Founded in 2022, Avanzanite now employs more than 110 people across Europe; the company serves more than 400 patients. About Zemcelpro ® Zemcelpro is an allogeneic hematopoietic stem...

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16.2 Safety findings were consistent with the established safety profile of ICOTYDE, with no...

Lilly and Hims & Hers expand access to Lilly's FDA-approved medicines

an FDA-approved Lilly medicine shipped directly to their home, all in one seamless experience. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound. “At Lilly, we are always looking for new ways to help more people...

Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

Roche announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen panel 3 (RP3). Designed for the automated cobas® eplex system, this flexible syndromic test offers up to five customizable panel...